The device, created by engineers and cancer scientists led by Professor David Flynn, represents an important step toward next-generation implantable photonic medical technologies
Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy improved disease-free survival for patients with intermediate- or high-risk localized prostate cancer.
An international research team led by the A*STAR Genome Institute of Singapore (A*STAR GIS) has developed HERRO, an artificial intelligence (AI) tool that could make it easier and more cost-effective to produce complete, high-quality genome assemblies.
Now, researchers at New York University say they have developed a new stent for surgery recovery. Their findings have been published in Advanced Healthcare Materials.
The findings, published in Nature Communications, pave the way for new types of prostheses, heart implants and sensors in the long term.
Researchers at the University of Massachusetts Amherst have designed non-toxic Salmonella bacteria to deliver viruses that are safe to humans but potent against liver and pancreatic cancer tumors—two cancers with an extremely poor prognosis.
Researchers at McMaster University have discovered a new antibiotic that kills some of the world’s most dangerous and drug-resistant bacteria—and does so by targeting a previously unknown vulnerability, opening the door to an entirely new class of treatments.
A Yale study published in the journal Bioactive Materials found that the medication lacosamide acts as a highly effective, dual-purpose treatment that relieves joint pain and reverses cartilage damage in osteoarthritis, especially when a specialized hydrogel delivers the drug directly into the joint.
Brain Navi Biotechnology Achieves Key Regulatory Milestone Following Recognition at the 22nd National Innovation Award
MILFORD, Mass., June 3, 2026 /PRNewswire/ — Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k) clearance.